We're developing a broad portfolio that has the potential to meaningfully improve millions of lives.

Vaxxine Program (Target)

Indications

Stages:

Preclinical

IND

Phase I

Phase II

Phase III

Marketed

NEURODEGENERATION

Preclinical

IND

Phase I

Phase II

Phase III

Marketed

UB-311
(Aβ)

Alzheimer’s

UB-312
(α-synuclein)

Parkinson’s, DLB, MSA

Tau

Alzheimer’s, Other

NEXT WAVE
CHRONIC

Preclinical

IND

Phase I

Phase II

Phase III

Marketed

UB-313
(CGRP)

Migraine

VXX-401
(PCSK9)

Hypercholesterolemia

INFECTIOUS
DISEASE

Preclinical

IND

Phase I

Phase II

Phase III

Marketed

UB-612

COVID-19


Clinical Trials
Vaxxinity is committed to developing safe and effective immunotherapeutic vaccines, with a goal of providing our next generation products as soon as possible through efficient product development. At this time, Vaxxinity’s investigational products can only be accessed through participation in a clinical trial. For detailed information on our ongoing clinical trials, please CLICK HERE. Vaxxinity does not currently offer an expanded access program.